• 1
    Wegener T, Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogast). Phytomedicine 2006; 13(Suppl. 5): 2035.
  • 2
    Melzer J, Rösch W, Reichling J, Brignoli R, Saller R. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004; 20: 127987.
  • 3
    Von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007; 102: 126875.
    Direct Link:
  • 4
    Hohenester B, Rühl A, Kelber O, Schemann M. The herbal preparation STW 5 (lberogast) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil 2004; 16: 76573.
  • 5
    Schemann M, Michel K, Zeller F, Hohenester B, Rühl A. Region-specific effects of STW 5 (Iberogast) and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13(Suppl. 5): 909.
  • 6
    Pilichiewicz AN, Horowitz M, Russo A et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102: 127683.
    Direct Link:
  • 7
    Schempp H, Weiser D, Kelber O, Elstner EF. Radical scavenging and anti-inflammatory properties of STW 5 (Iberogast) and its components. Phytomedicine 2006; 13(Suppl. 5): 3644.
  • 8
    Khayyal MT, Seif-El-Nasr M, El-Ghazaly MA, Okpanyi SN, Kelber O, Weiser D. Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast) and its components against ulcers and rebound acidity. Phytomedicine 2006; 13(Suppl. 5): 5666.
  • 9
    Germann I, Hagelauer D, Kelber O et al. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast). Phytomedicine 2006; 13(Suppl. 5): 4550.
  • 10
    Kelber O, Wittwer A, Lapke C et al. Ex vivo/in vitro absorption of STW 5 (Iberogast) and its extract components. Phytomedicine 2006; 13(Suppl. 5): 10713.
  • 11
    Wagner H. Multitarget therapy – the future of treatment for more than just functional dyspepsia. Phytomedicine 2006; 13(Suppl. 5): 1229.
  • 12
    Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004; 19: 2719.
  • 13
    Liu JP, Yang M, Liu YX, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006; 1: CD004116.
  • 14
    Ammon HP, Kelber O, Okpanyi SN. Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle. Phytomedicine 2006; 13(Suppl. 5): 6774.
  • 15
    Larsson MH, Simrén M, Thomas EA, Bornstein JC, Lindström E, Sjövall H. Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome. Neurogastroenterol Motil 2008; 19: 81220.
  • 16
    Andresen V, Camilleri M, Busciglio IA et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007; 133: 7618.
  • 17
    Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 27: 68596.
  • 18
    Harris LA, Crowell MD. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther 2007; 9: 40310.
  • 19
    Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging 2008; 3: 35764.
  • 20
    Schicho R, Krueger D, Zeller F et al. Hydrogen sulfide is a novel prosecretory neuromodulator in the Guinea-pig and human colon. Gastroenterology 2006; 131: 154252.
  • 21
    Breunig E, Michel K, Zeller F, Seidl S, Weyhern CW, Schemann M. Histamine excites neurones in the human submucous plexus through activation of H1, H2, H3 and H4 receptors. J Physiol 2007; 583: 73142.
  • 22
    Neunlist M, Peters S, Schemann M. Multisite optical recording of excitability in the enteric nervous system. Neurogastroenterol Motil 1999; 11: 393402.
  • 23
    Thiagarajah JR, Broadbent T, Hsieh E, Verkman AS. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 2004; 126: 5119.
  • 24
    Xue J, Askwith C, Javed NH, Cooke HJ. Autonomic nervous system and secretion across the intestinal mucosal surface. Auton Neurosci 2007; 133: 5563.
  • 25
    Schultheiss G, Siefjediers A, Diener M. Muscarinic receptor stimulation activates a Ca(2+)-dependent Cl(−) conductance in rat distal colon. J Membr Biol 2005; 204: 11727.
  • 26
    Liu CY, Müller MH, Glatzle J et al. The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 75964.
  • 27
    Sibaev A, Yuece B, Kelber O et al. STW 5 (Iberogast) and its individual herbal components modulate intestinal electrophysiology of mice. Phytomedicine 2006; 13(Suppl. 5): 809.
  • 28
    Abdel-Aziz H, Wadie W, Khayyal MT, Kelber O, Okpanyi S, Weiser D. Pharmacological evidence for the anti-inflammatory effect of STW 5 in colonic inflammation in vivo. Planta Med 2007; 72: 992 (abstract).
  • 29
    Abdel-Aziz H, Wadie W, Kelber O, Vinson B, Weiser D, Khayyal MT. Anti-inflammatory effect of STW 5 in colonic inflammation in vivo. Gut 2007; 56: A154.
  • 30
    Schemann M, Krueger D, Gruber L et al. Action profile of the phytomedicine STW 5 suggests novel indications. Neurogastroenterol Motil 2008; 20(Suppl. 1): 95.